Schedule 13G ownership disclosure

Compass Therapeutics Inc

Common Stock, $0.0001 par value per share · CUSIP: 20454B104

Event date: 2025-08-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Suvretta Capital Management, LLC

    Shares: 14,101,159.00 · Class: 8.2%

  • Averill Master Fund, Ltd.

    Shares: 12,229,050.00 · Class: 7.1%

  • Aaron Cowen

    Shares: 14,101,159.00 · Class: 8.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000919574-25-005042
Form type
SCHEDULE 13G/A
Filer
Compass Therapeutics, Inc.
CIK
CIK 1738021
Filed
Aug 21, 2025
Reporting period
Aug 13, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub